The Oncology Institute, Inc. Warrant - TOIIW STOCK NEWS

The Oncology Institute (TOI) has joined Lantern's specialty care platform, expanding access to cancer care for Lantern members across TOI's community clinics in 5 states. The partnership aims to provide advanced cancer treatment while reducing financial burden for patients. TOI, with over 120 clinicians and 700 team members across 70+ clinic locations, serves a population of over 1.8 million patients. The collaboration focuses on delivering optimal outcomes and patient satisfaction through value-based oncology care, including clinical trials and transfusion services.

The Oncology Institute (NASDAQ: TOI) and the American Journal of Managed Care® (AJMC) are partnering to co-host a symposium on value-based cancer care on October 24, 2024, in Miami, Florida. The event is part of AJMC's Institute for Value-Based Medicine (IVBM), a leading forum for expert insights on implementing value-based care in oncology and population health.

The symposium will feature panel discussions with healthcare professionals, including physicians, practice administrators, and payors, focusing on key learnings and emerging opportunities. Dr. Daniel Virnich, CEO of The Oncology Institute, will chair the event. Other TOI executives moderating panels include Dr. Yale Podnos (CMO), Jordan McInerney (CDO), and Ray Parzik (VP).

The Oncology Institute (TOI), a leading value-based oncology group, has expanded into Oregon with the opening of two new specialty cancer clinics in Portland and Salem. This marks TOI's first capitated partnership in the market, with plans for further expansion across the state. The new clinics will offer cutting-edge cancer care services, providing a vital option for patients in the Pacific Northwest.

Dr. Dan Virnich, CEO of TOI, emphasized the company's commitment to providing advanced care in local communities, focusing on optimal outcomes, patient satisfaction, and minimizing financial burdens. Dr. Patan Gultawatvichai, Medical Director of TOI in Oregon, highlighted the company's dedication to redefining oncology care through value-based models.

TOI, founded in 2007, serves over 1.8 million patients across more than 70 clinic locations with over 120 employed clinicians and 700 team members. The company offers advanced services including clinical trials and transfusions, aiming to change oncology for the better.

The Oncology Institute (NASDAQ: TOI) has announced a CFO transition. Mihir Shah, the current CFO, will leave the organization on October 14, 2024. Rob Carter, Senior Vice President of Finance, will be promoted to Chief Financial Officer. Carter, who joined TOI in 2021, brings over a decade of finance leadership experience from notable healthcare institutions.

CEO Dr. Daniel Virnich expressed excitement about Carter's promotion, citing his experience in oncology and large health systems. Virnich also thanked Shah for his contributions, including leading TOI through its early years as a public company and improving capabilities in reporting, compliance, and analytics.

Carter stated his honor in becoming TOI's next CFO and his belief in the company's future growth and innovation. TOI, founded in 2007, delivers specialized, value-based cancer care in community settings, serving over 1.8 million patients with 126 employed clinicians and more than 700 teammates across 70+ clinic locations.

The Oncology Institute (NASDAQ: TOI) reported its Q2 2024 financial results and updated full-year guidance. Key highlights include:

- 22.9% increase in consolidated revenue to $99 million
- 76% growth in Dispensary segment revenue
- Net loss of $15.5 million, improved from $16.9 million in Q2 2023
- Adjusted EBITDA of $(8.7) million
- Cash and equivalents of $46.4 million as of June 30, 2024

TOI signed 3 new capitation contracts across 2 states, bringing the total to 10 new contracts in 2024. The company is exploring strategic alternatives to maximize shareholder value. Despite a decrease in gross profit, TOI expects significant improvement in net loss and adjusted EBITDA in H2 2024, driven by improving IV margins and newly signed capitated contracts going live in Q3.

The Oncology Institute (TOI), a leading value-based oncology group in the United States, has announced its second quarter 2024 earnings release date and conference call details. The company will release its financial results on Tuesday, August 13, 2024, after the market close. This will be followed by a conference call at 5:00 p.m. Eastern Time on the same day.

Investors can access the call by dialing 1-877-407-0789 (US) or 1-201-689-8562 (international). A replay will be available until August 20, 2024, accessible via 1-844-512-2921 (US) or 1-412-317-6671 (international) with passcode 13747491. Additionally, a simultaneous webcast will be available on the company's Investor Relations website.

The Oncology Institute (NASDAQ: TOI) will participate in two major investor conferences. CEO Dr. Daniel Virnich will represent TOI at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00am ET in New York City. He will also join the Truist Securities Healthcare Disruptors & Digital Health Summit on June 26, 2024, at 1:00pm ET, also in New York City. Interested parties can access live webcasts and replays through the company's Investor Relations website.

The Oncology Institute (NASDAQ: TOI) has announced that its executives will participate in multiple panel presentations at the APG 2024 Spring Conference in San Diego. Dr. Yale Podnos, Chief Medical Officer, will discuss the use of artificial intelligence in oncology practices during the breakout session titled 'AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients'. Additionally, CEO Dr. Daniel Virnich will join a panel discussing global risk management in pharmaceuticals. The event takes place in May 2024 and highlights the institute's focus on integrating advanced technology and risk management strategies in oncology.

The Oncology Institute (NASDAQ: TOI) announced its Q1 2024 financial results, reporting a 24.2% increase in consolidated revenue to $95 million. Despite this, the gross profit decreased by 15.1% to $12 million, with net losses reducing to $19.9 million from the previous year's $30 million. The net loss per share improved to $(0.22) from $(0.33). Adjusted EBITDA was $(10.9) million, higher than the $(7.4) million from the prior year. The company ended Q1 with $66 million in cash and short-term investments. Operationally, TOI signed seven new capitation and value-based contracts across three states, integrated a capitated risk contract with a health plan in Florida, and expanded its MSO model in Florida. The firm also increased the number of scripts dispensed by 70% and hired seven new providers, bringing the total to 126 employed providers across 73 clinics. CEO Daniel Virnich highlighted the company's revenue growth and new partnerships as key milestones.